A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Novo’s 2024 Sustainability Report demonstrates that Novo remains committed to sustainability as we execute our exploration ...

Novo is in a strong financial position to continue its exploration focus on Western Australia and Victoria, with no debt and ...

Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...

Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company developing a new class of proteasome ...

On the Board of Page, Dr. Gaugler joins Prof. Nicola Aceto, scientific founder, Prof. Christoph Rochlitz, MD, co-founder and CMO, as well as Daniele Scarinci, President and CEO and Ciro Spedaliere, ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

“That’s the grand vision,” says Ms. Yu. The company has provided its bioplastic solution to Amazon, Novo Nordisk, and Sodexo, ...